<DOC>
	<DOC>NCT02020512</DOC>
	<brief_summary>This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.</brief_summary>
	<brief_title>A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Diagnosis of openangle glaucoma or ocular hypertension No use of LumiganÂ® in the past 3 months Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>